Cargando…
SGMS2 in primary osteoporosis with facial nerve palsy
Pathogenic heterozygous variants in SGMS2 cause a rare monogenic form of osteoporosis known as calvarial doughnut lesions with bone fragility (CDL). The clinical presentations of SGMS2-related bone pathology range from childhood-onset osteoporosis with low bone mineral density and sclerotic doughnut...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598846/ https://www.ncbi.nlm.nih.gov/pubmed/37886644 http://dx.doi.org/10.3389/fendo.2023.1224318 |
_version_ | 1785125644581994496 |
---|---|
author | Pihlström, Sandra Richardt, Sampo Määttä, Kirsi Pekkinen, Minna Olkkonen, Vesa M. Mäkitie, Outi Mäkitie, Riikka E. |
author_facet | Pihlström, Sandra Richardt, Sampo Määttä, Kirsi Pekkinen, Minna Olkkonen, Vesa M. Mäkitie, Outi Mäkitie, Riikka E. |
author_sort | Pihlström, Sandra |
collection | PubMed |
description | Pathogenic heterozygous variants in SGMS2 cause a rare monogenic form of osteoporosis known as calvarial doughnut lesions with bone fragility (CDL). The clinical presentations of SGMS2-related bone pathology range from childhood-onset osteoporosis with low bone mineral density and sclerotic doughnut-shaped lesions in the skull to a severe spondylometaphyseal dysplasia with neonatal fractures, long-bone deformities, and short stature. In addition, neurological manifestations occur in some patients. SGMS2 encodes sphingomyelin synthase 2 (SMS2), an enzyme involved in the production of sphingomyelin (SM). This review describes the biochemical structure of SM, SM metabolism, and their molecular actions in skeletal and neural tissue. We postulate how disrupted SM gradient can influence bone formation and how animal models may facilitate a better understanding of SGMS2-related osteoporosis. |
format | Online Article Text |
id | pubmed-10598846 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105988462023-10-26 SGMS2 in primary osteoporosis with facial nerve palsy Pihlström, Sandra Richardt, Sampo Määttä, Kirsi Pekkinen, Minna Olkkonen, Vesa M. Mäkitie, Outi Mäkitie, Riikka E. Front Endocrinol (Lausanne) Endocrinology Pathogenic heterozygous variants in SGMS2 cause a rare monogenic form of osteoporosis known as calvarial doughnut lesions with bone fragility (CDL). The clinical presentations of SGMS2-related bone pathology range from childhood-onset osteoporosis with low bone mineral density and sclerotic doughnut-shaped lesions in the skull to a severe spondylometaphyseal dysplasia with neonatal fractures, long-bone deformities, and short stature. In addition, neurological manifestations occur in some patients. SGMS2 encodes sphingomyelin synthase 2 (SMS2), an enzyme involved in the production of sphingomyelin (SM). This review describes the biochemical structure of SM, SM metabolism, and their molecular actions in skeletal and neural tissue. We postulate how disrupted SM gradient can influence bone formation and how animal models may facilitate a better understanding of SGMS2-related osteoporosis. Frontiers Media S.A. 2023-10-11 /pmc/articles/PMC10598846/ /pubmed/37886644 http://dx.doi.org/10.3389/fendo.2023.1224318 Text en Copyright © 2023 Pihlström, Richardt, Määttä, Pekkinen, Olkkonen, Mäkitie and Mäkitie https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Pihlström, Sandra Richardt, Sampo Määttä, Kirsi Pekkinen, Minna Olkkonen, Vesa M. Mäkitie, Outi Mäkitie, Riikka E. SGMS2 in primary osteoporosis with facial nerve palsy |
title |
SGMS2 in primary osteoporosis with facial nerve palsy |
title_full |
SGMS2 in primary osteoporosis with facial nerve palsy |
title_fullStr |
SGMS2 in primary osteoporosis with facial nerve palsy |
title_full_unstemmed |
SGMS2 in primary osteoporosis with facial nerve palsy |
title_short |
SGMS2 in primary osteoporosis with facial nerve palsy |
title_sort | sgms2 in primary osteoporosis with facial nerve palsy |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598846/ https://www.ncbi.nlm.nih.gov/pubmed/37886644 http://dx.doi.org/10.3389/fendo.2023.1224318 |
work_keys_str_mv | AT pihlstromsandra sgms2inprimaryosteoporosiswithfacialnervepalsy AT richardtsampo sgms2inprimaryosteoporosiswithfacialnervepalsy AT maattakirsi sgms2inprimaryosteoporosiswithfacialnervepalsy AT pekkinenminna sgms2inprimaryosteoporosiswithfacialnervepalsy AT olkkonenvesam sgms2inprimaryosteoporosiswithfacialnervepalsy AT makitieouti sgms2inprimaryosteoporosiswithfacialnervepalsy AT makitieriikkae sgms2inprimaryosteoporosiswithfacialnervepalsy |